Shares of Novo Nordisk and rival Eli Lilly fell on Tuesday after a report said price cuts are coming for popular weight-loss drugs.
Novo Nordisk and Eli Lilly shares both fall after Novo’s price-cut plan for Ozempic and Wegovy
Previous ArticleFederal Student Loan Losses Expected To Drop to 4% in 2026
Related Posts
Add A Comment